Epifast 250mg Tablet contains Levetiracetam, an antiepileptic agent indicated for the treatment of partial-onset seizures, myoclonic seizures, and primary generalized tonic-clonic seizures in patients with epilepsy. Levetiracetam acts by modulating synaptic neurotransmitter release through binding to the synaptic vesicle protein SV2A, thereby reducing neuronal excitability and seizure propagation. Epifast is commonly prescribed as adjunctive therapy in adults and pediatric patients aged four years and above, and as monotherapy in newly diagnosed epilepsy. The 250mg dosage provides an effective starting point for titration based on clinical response and tolerability. Epifast is generally well tolerated; common adverse effects include somnolence, dizziness, headache, and fatigue. Caution is advised in patients with renal impairment, as dosage adjustments may be necessary. Epifast does not induce or inhibit hepatic enzymes significantly, minimizing drug-drug interactions. Patients should be monitored regularly for behavioral changes, mood alterations, or signs of hypersensitivity. Epifast should be administered consistently, with or without food, to maintain stable plasma concentrations. Discontinuation should be gradual to reduce the risk of increased seizure frequency. Overall, Epifast 250mg Tablet is a reliable option for managing various seizure types, improving patient quality of life through effective seizure control.